(:CATB)

Sep 08, 2021 08:00 am ET
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. (“Astria” or the “Company”). The name Astria originates from the Greek word for star, reflecting the Company’s commitment to having pat
Aug 09, 2021 04:10 pm ET
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Aug 04, 2021 08:00 am ET
Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET. The session entitled “HAE There- D
Jul 07, 2021 08:00 am ET
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual La
Jun 16, 2021 08:32 am ET
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?
NEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT.
May 14, 2021 08:00 am ET
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming
May 13, 2021 04:10 pm ET
 Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Mar 11, 2021 04:10 pm ET
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
Mar 02, 2021 08:00 am ET
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences   
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual inv
Jan 29, 2021 08:00 am ET
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases. Concurrent with the acquisition of Quellis, Catabas
Nov 12, 2020 04:10 pm ET
Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.
Oct 26, 2020 05:00 pm ET
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonex
Sep 28, 2020 08:00 am ET
Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Societ
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for Duchenne muscular dystrophy (DMD) in poster presentations at the Virtual 25th International Congress of the World Muscle Society. The posters include new
Sep 23, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program, in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD), during the 25th International Congress of the World Muscle Society which begi
Sep 21, 2020 08:00 am ET
Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has promoted Noah Clauser to Chief Financial Officer. Mr. Clauser brings close to 20 years of financial experience to this role and has been with Catabasis for 9 years, most recently as Vice President, Finance.
Sep 08, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about edasalonexent, in Phase 3 development for the treatment of Duchenne muscular dystrophy, at the following virtu
Sep 02, 2020 08:00 am ET
Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will be holding a virtual key opinion leader (KOL) event to discuss edasalonexent, currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD), on Friday, September 11,.2020 at 9:00am ET.
Aug 10, 2020 04:10 pm ET
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business progress.
Aug 05, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the virtual 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 8:00am ET.
Aug 04, 2020 08:00 am ET
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today it entered into an agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit biotechnology organization, to assess CAT-5571 as a potential oral therapy to promote autophagy and clear persistent l
Jul 27, 2020 08:00 am ET
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2020 financial results after the Nasdaq Global Market close on Monday, August 10, 2020.
Jul 15, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the Parent Project Muscular Dystrophy (PPMD) Virtual Annual Conference, which be
Jun 29, 2020 04:10 pm ET
 Catabasis Joins Russell 3000® Index
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has joined the broad-market Russell 3000® Index at the conclusion of the 2020 Russell Indexes annual reconstitution, effective after the US market opened today.
Jun 12, 2020 08:00 am ET
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger brings to Catabasis more than 20 years of experience at commercial-stage pharmaceutical and biotechnology companies.
May 12, 2020 04:10 pm ET
Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2020 and reviewed recent business progress.
May 12, 2020 08:00 am ET
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) in poster presentations at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session. The three posters
Apr 28, 2020 08:00 am ET
Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2020 financial results after the Nasdaq Global Market close on Tuesday, May 12, 2020.
Apr 17, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session later this month.
Mar 25, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide a business update at the upcoming Solebury Trout Virtual Investor Conference on Tuesday, March 31, 2020 at 12:30pm EDT.
Mar 24, 2020 04:00 pm ET
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences industry. At the event, management teams will present a business overview and highlights using an online, digital meeting format.
Mar 18, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) during the Muscular Dystrophy Association (MDA) Virtual Clinical Trials Session on Tuesday
Mar 10, 2020 08:05 am ET
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2019 and reviewed recent business progress.
Feb 25, 2020 08:00 am ET
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2019 financial results before the Nasdaq Global Market open on Tuesday, March 10, 2020. Jill C. Milne, Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on
Feb 21, 2020 08:00 am ET
Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy, organized by Parent Project, i
Feb 03, 2020 04:05 pm ET
Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of an aggregate of 5,290,000 shares of common stock at a public offering price of $5.00 per share, including
Jan 30, 2020 09:00 am ET
Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,600,000 shares of common stock at a public offering price of $5.00 per share. The offering is expected to clos
Jan 29, 2020 04:01 pm ET
Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to wh
Jan 08, 2020 08:00 am ET
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for a Phase 2 trial of edasalonexent, a novel NF-kB inhibitor, in non-ambulatory DMD patient
Dec 16, 2019 08:00 am ET
Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the results from an analysis of the baseline characteristics of the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). The analysis shows that overall the patients enrolled in the Phase 3 trial have si
Nov 07, 2019 08:05 am ET
Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2019 and reviewed recent business progress.
Oct 24, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developmen
Oct 18, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the Child Neurology Society 48th Annual Meeting to be held October 23-2
Oct 05, 2019 08:00 am ET
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, edasalonexent slowed disease progression compared to the off-treatment control period and was well tolerated through more than 55 cumula
Sep 30, 2019 04:05 pm ET
Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). The target enrollment of 125 boys was exceeded due to strong interest from our 40 clinical sites in 8 countries and the support
Sep 27, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the 24th International Congress of the World Muscle Society, being held October 1-5,
Sep 26, 2019 08:00 am ET
Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and the Jain Foundation
Sep 25, 2019 08:00 am ET
Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Andrew A. Komjathy as Chief Commercial Officer. Mr. Komjathy brings to Catabasis more than 30 years of experience in commercial operations and sales including extensive experience in rare diseases.
Aug 08, 2019 08:05 am ET
Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2019 and reviewed recent business progress.
Aug 07, 2019 08:00 am ET
Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Hugh M. Cole to its Board of Directors. Mr. Cole has more than 20 years of pharmaceutical business development experience and is currently the Chief Business Officer and Head of Corporate Development at Jounce Therapeutics.
Aug 06, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 4:15pm ET at the Parker New York in New York, NY.
Jul 25, 2019 08:30 am ET
Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2019 financial results before the Nasdaq Global Market open on Thursday, August 8, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate development
Jun 27, 2019 08:00 am ET
Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD) this week at the Parent Project Muscular Dystrophy (PPMD) 25th Annual Conference.
Jun 21, 2019 09:45 am ET
Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD). Edasalonexent is a novel NF-kB inhibitor in Phase 3 d
Jun 18, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD), at two upcoming meetings: the Symposium on Muscle-Bone Interaction in
May 14, 2019 08:05 am ET
Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2019, and reviewed recent business progress.
May 02, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy (DMD) from the MoveDMD trial open-label extension at the American Academy of Neurology 71st Annu
Apr 30, 2019 08:00 am ET
Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2019 financial results before the Nasdaq Global Market open on Tuesday, May 14, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide a
Apr 12, 2019 08:10 am ET
Research Report Identifies TTM Technologies, Zumiez, Global Net Lease, Catabasis Pharmaceuticals, BioPharmX, and Protalix BioTherapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forwa
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TTM Technologies, Inc. (NASDAQ:TTMI), Zumiez Inc. (NASDAQ:ZUMZ), Global...
Apr 01, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Phase 3 PolarisDMD trial, at two major medical meetings in April: the
Mar 14, 2019 08:05 am ET
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2018, and reviewed recent business progress.
Mar 13, 2019 08:00 am ET
Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 8:00am ET at the Westin New York Grand
Feb 28, 2019 08:00 am ET
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2018 financial results before the Nasdaq Global Market open on Thursday, March 14, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30
Feb 19, 2019 08:00 am ET
Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared additional clinical results from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, boys with Duchenne muscular dystrophy (DMD) treated with edasalonexent on average grew
Feb 14, 2019 08:00 am ET
Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years of pharmaceutical development and operations experience and is currently the Executive Vice President, Glob
Feb 06, 2019 09:00 am ET
Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a public offering price of $5.00 per unit. Each unit is comprised of on
Feb 05, 2019 04:01 pm ET
Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be
Jan 29, 2019 07:55 am ET
New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tiffany & Co. (NYSE:TIF), CarMax, Inc. (NYSE:KMX), Cars.com Inc....
Jan 04, 2019 08:00 am ET
Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Gregg Lapointe to its Board of Directors. Mr. Lapointe has three decades of commercial and financial experience and he is Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, I
Jan 03, 2019 08:08 am ET
Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD trial for edasalonexent (CAT-1004) in Duchenne muscular dyst
Dec 24, 2018 08:00 am ET
Catabasis Pharmaceuticals Announces Reverse Stock Split
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will effect a one-for-ten reverse stock split of its common stock that will be effective on December 28, 2018. The Company's common stock will begin trading on a split-adjusted basis when the market o
Nov 28, 2018 08:55 am ET
Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MyoKardia, Inc. (NASDAQ:MYOK), Bristow Group Inc (NYSE:BRS), The Chefs'...
Nov 27, 2018 08:00 am ET
Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were
Nov 13, 2018 08:05 am ET
Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2018, and reviewed recent business progress.
Nov 13, 2018 07:45 am ET
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystr
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced a collaboration with Pradeep Mammen, MD, FACC, FAHA, founder and Medical Director of the Neuromuscular Cardiomyopathy Clinic at the University of Texas Southwestern (UT Southwestern) Medical Center as well as
Nov 02, 2018 08:00 am ET
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar: “PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor, in Duchenne Muscular Dystrophy,” on Wednesday, November 7, 2018 at 1:00pm ET.
Oct 30, 2018 08:00 am ET
Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on Tuesday, November 13
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2018 financial results before the Nasdaq Global Market open on Tuesday, November 13, 2018. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provi
Oct 18, 2018 08:25 am ET
Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Catabasis...
Oct 03, 2018 08:00 am ET
Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new data supporting magnetic resonance imaging (MRI) T2 as a potential marker of clinical outcome in boys with Duchenne Muscular Dystrophy (DMD). Data from ImagingDMD, the largest natural history database of MR
Sep 25, 2018 08:00 am ET
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of PolarisDMD, the Company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy (DMD). Edasalonexent inhibits NF-kB, which is the key link between loss of dystrophin and disease path
Sep 19, 2018 08:00 am ET
Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will share three presentations, including in the late breaking session, at the 23rd International Congress of the World Muscle Society, being held October 2 – 6, 2018, at the Interc
Aug 27, 2018 07:45 am ET
Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA),...
Aug 09, 2018 08:05 am ET
Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2018, and reviewed recent business progress.
Aug 08, 2018 08:00 am ET
Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30pm ET at the Le Parker Meridien Hote
Jul 26, 2018 08:00 am ET
Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, August 9
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2018 financial results before the NASDAQ Global Market open on Thursday, August 9, 2018. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provid
Jul 09, 2018 08:00 am ET
Catabasis Pharmaceuticals Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced plans for the Phase 3 POLARIS DMD trial with edasalonexent in patients with Duchenne muscular dystrophy (DMD). Catabasis plans to initiate the global POLARIS DMD trial in the second half of 2018 with top-line
Jun 26, 2018 07:45 am ET
Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics — Research Highlights Growth, Revenue, and Consolidated Resu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Manitowoc Company, Inc. (NYSE:MTW), Omeros Corporation (NASDAQ:OMER),...
Jun 25, 2018 03:40 pm ET
Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD® Trial
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected by Duchenne muscular dystrophy (DMD). NF-kB is a fundamental
Jun 22, 2018 04:05 pm ET
Catabasis Pharmaceuticals Announces Closing of $42M Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of an aggregate of 42,000,000 units. Each unit is comprised of one share of common stock and one common warrant to purchase one share of com
Jun 20, 2018 09:10 am ET
Catabasis Pharmaceuticals Announces Pricing of $42 Million Underwritten Public Offering
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten offering of an aggregate of 42,000,000 units. Each unit is comprised of one share of common stock and one common warrant to pur
Jun 18, 2018 08:00 am ET
Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from the MoveDMD® trial of edasalonexent (CAT-1004) at the New Directions in Biology and Disease of Skeletal Muscle Conference, the 2018 Parent Project Muscular Dystrophy (
May 10, 2018 08:05 am ET
Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2018, and reviewed recent business progress.
May 09, 2018 08:15 am ET
Market Trends Toward New Normal in Church & Dwight Co., Rent-A-Center, Teradata, Catabasis Pharmaceuticals, Tronox, and Callaway Golf — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Church Dwight Co., Inc. (NYSE:CHD), Rent-A-Center, Inc. (NASDAQ:RCII),...
May 03, 2018 08:00 am ET
Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2018 financial results before the NASDAQ Global Market open on Thursday, May 10, 2018. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide a
Apr 25, 2018 05:00 pm ET
Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne muscular dystrophy (DMD) in the MoveDMD trial through 48 weeks of edasalonexent treatment. Both magnetic
Apr 18, 2018 08:00 am ET
Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present new magnetic resonance imaging (MRI) data from the open-label extension MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD) at the American Aca
Apr 17, 2018 04:01 pm ET
Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). Catabasis is prioritizing this program to
Mar 20, 2018 08:00 am ET
Catabasis Pharmaceuticals to Present at Oppenheimer’s 28th Annual Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 28th Annual Healthcare Conference on March 21, 2018 at 10:20am ET at the Westin New York Grand
Mar 15, 2018 04:10 pm ET
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2017, and reviewed recent business progress.
Mar 08, 2018 08:00 am ET
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2017 financial results after the NASDAQ Global Market close on Thursday, March 15, 2018. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30p
Mar 07, 2018 08:15 am ET
Detailed Research: Economic Perspectives on RPC, Catabasis Pharmaceuticals, Zayo Group, Catalent, ARRIS International, and McCormick & Company — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RPC, Inc. (NYSE:RES), Catabasis Pharmaceuticals, Inc....
Feb 13, 2018 08:00 am ET
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive efficacy and safety results showing preservation of muscle function and sustained disease-modifying effects in boys with Duchene muscular dystrophy (DMD) in the MoveDMD trial open-label extension f
Dec 06, 2017 02:00 am ET
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
LIESTAL, Switzerland, OXFORD, England and CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Santhera Pharmaceuticals (SIX:SANN), Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), Catabasis Pharmaceuticals (NASDAQ:CATB) and Duchenne UK are pleased to announce a collaboration to host a Duchenne Muscular Dystrophy...
Nov 21, 2017 08:00 am ET
Catabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present an overview of the company in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at
Nov 13, 2017 08:20 am ET
Analysis: Positioning to Benefit within Catabasis, Flowserve, MGIC Investment, Arrowhead, Silver Spring, and Live Nation – Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), Flowserve Corporation...
Nov 09, 2017 04:10 pm ET
Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2017, and reviewed recent business progress.
Nov 02, 2017 08:00 am ET
Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2017 financial results after the NASDAQ Global Market close on Thursday, November 9, 2017. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provi
Oct 26, 2017 08:00 am ET
Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that CAT-5571, which restores host defense by activating autophagy, will be presented in a poster at the 31st Annual North American Cystic Fibrosis Conference (NACFC). NACFC is being held November 2
Oct 04, 2017 04:30 am ET
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Tr
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive efficacy results showing sustained disease-modifying effects in the MoveDMD trial open-label extension following 24 and 36 weeks of treatment with edasalonexent. Across all key assessments of muscl
Nov 16, 2016 01:00 pm ET

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.